Conference abstractPublished 27 Oct 2016
Development and evaluation of lipid-polymer hybrid systems for the treatment of benign prostate hyperplasia
Ankara University, Turkey
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Benign Prostate Hyperplasia (BPH) is a progressive-proliferative disorder commonly observed in males over 50 years of age and the incidence is on the rise due to aging population. Common methods of clinical treatment for the disorder included drug therapy, sometime lasting for years and surgical approach including transurethral resection. An effective treatment strategy could focus on using new generation agents which functions on activating apoptosis mechanisms of prostate cells. From this perspective, we designed a series of lipid-polymer hybrid nanoparticulate drug carriers of a potent hexokinase-2 enzyme inhibitor-lonidamine-on the basis of design of experiment (DoE) approach. Oral application of lonidamine for the BPH treatment is limited due to the low water solubility, low bioavailability and the liver toxicity observed after the long-term treatment. These limitations could be solely overcome by designing and improving the nano-sized drug delivery systems of lonidamine. Within this context, a systematic screening study was employed to design the lipid-polymer hybrid nanoparticles of lonidamine and the in-vitro characteristics of the formulations were evaluated in terms of the major features of the carriers. After the selection of the optimized formulation based on the important outcomes of the design, in-vivo effectiveness of the system was evaluated on rats following BPH development. The optimized formulation was directly injected into the rat prostates that had been created BPH models and prostatic index was calculated to determine the level of regression in hyperplasic structure. As a result of this study, a significant progress has been achieved in treatment of BPH and a new alternative treatment method has been occurred with lonidamine loaded hybrid nanoparticles to increase the therapeutic efficiency of the drug.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ceyda Tuba Sengel-Turk”
